0
Correspondence |

Important Antiretroviral Drug Interactions With Benzodiazepines Used for Sedation During BronchoscopyAntiretroviral Drug Interactions With Sedation FREE TO VIEW

Ricardo J. José, MBChB, DA(SA); Neal Marshall, MPharm, MSc; Marc C. Lipman, MD
Author and Funding Information

From the Department of Respiratory Medicine (Drs José and Lipman) and the Ian Charleson Centre for HIV Medicine (Mr Marshall), Royal Free Hospital.

Correspondence to: Ricardo J. José, MBChB, DA(SA), Department of Respiratory Medicine, Royal Free Hospital, Pond St, London, NW3 2PL, England; e-mail: rjose@doctors.org.uk


Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Mr Marshall has received honoraria for speaker fees, conference registration, and travel expenses from Janssen, Bristol-Myers Squibb, ViiV Healthcare, Abbott, Gilead Science, and Merck Sharp & Dohme. Drs José and Lipman have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2012 American College of Chest Physicians


Chest. 2012;141(4):1125. doi:10.1378/chest.11-2944
Text Size: A A A
Published online

To the Editor:

We read with interest the article by Wahidi et al1 in CHEST (November 2011). We are concerned that the section on midazolam did not provide up-to-date information on interactions between this drug and highly active antiretroviral therapy (ART) used in HIV-infected individuals.

The study that is quoted in the consensus statement suggests that higher doses of midazolam may be needed in certain HIV-infected populations.2 We believe this reflects the situation in IV-drug users who are HIV-positive (the main HIV study group) and are likely to have acquired a tolerance to benzodiazepines through prolonged use. There is no detail provided on ART usage; therefore, the conclusions should not be extrapolated to all patients with HIV.

The majority of current ART regimens contain either potent cytochrome P450 enzyme 3A4 (CYP3A4) inhibitors, such as the HIV protease inhibitor ritonavir, or enzyme inducers, such as the non-nucleoside reverse transcriptase inhibitors efavirenz or nevirapine. Midazolam is extensively metabolized by CYP3A4 and coadministration with, for example, lopinavir/ritonavir results in a fourfold increase in midazolam bioavailability (area under the curve) after parenteral administration.3 This may result in prolonged sedation and other adverse effects such as arrhythmias.

Diazepam at reduced doses has been used in clinical practice with ritonavir (100 to 200 mg daily), although at higher ritonavir doses, it is contraindicated.4 Alternatively, lorazepam has the least potential for interaction with ART of all the currently available benzodiazepines5 used in bronchoscopy. It may be considered in this scenario (where available) despite its disadvantage of a longer onset of action and duration of sedation. The use of benzodiazepines for other patient groups receiving CYP3A4 inhibitors such as macrolide antibiotics, itraconazole, and the new hepatitis C virus NS3 inhibitors (boceprevir and telaprevir) should also be undertaken with caution.

Conversely, the concomitant administration of CYP3A4 inducers such as efavirenz, or rifamycin antibiotics may lead to therapeutic failure of standard-dose benzodiazepines. Dose escalation should be performed with careful clinical and physiologic monitoring.

The response to sedation in patients who are HIV-positive is unpredictable. The choice of sedative and its dosage must be tailored to the individual’s history and most importantly his or her concurrent medication. Increased postprocedure monitoring is mandatory.

Wahidi MM, Jain P, Jantz M, et al. American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients. Chest. 2011;1405:1342-1350 [CrossRef] [PubMed]
 
Chhajed PN, Wallner J, Stolz D, et al. Sedative drug requirements during flexible bronchoscopy. Respiration. 2005;726:617-621 [PubMed]
 
Abbott Laboratories LtdAbbott Laboratories Ltd Summary of product characteristics for Kaletra 200/50 mg tablets. Electronic Medicines Compendium Web site.http://www.medicines.org.uk/EMC/medicine/18442/SPC/Kaletra+200+mg+50+mg+film-coated+tablets/. Accessed December 11, 2011.
 
Abbott Laboratories LtdAbbott Laboratories Ltd Summary of product characteristics for Norvir 100 mg tablets. Electronic Medicines Compendium Web site.http://www.medicines.org.uk/EMC/medicine/22952/SPC/Norvir+100mg+film-coated+tablets/. Accessed December 11, 2011.
 
University of Liverpool Drug Interactions Web site.http://www.hiv-druginteractions.org/Interactions.aspx. Accessed December 11, 2011.
 

Figures

Tables

References

Wahidi MM, Jain P, Jantz M, et al. American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients. Chest. 2011;1405:1342-1350 [CrossRef] [PubMed]
 
Chhajed PN, Wallner J, Stolz D, et al. Sedative drug requirements during flexible bronchoscopy. Respiration. 2005;726:617-621 [PubMed]
 
Abbott Laboratories LtdAbbott Laboratories Ltd Summary of product characteristics for Kaletra 200/50 mg tablets. Electronic Medicines Compendium Web site.http://www.medicines.org.uk/EMC/medicine/18442/SPC/Kaletra+200+mg+50+mg+film-coated+tablets/. Accessed December 11, 2011.
 
Abbott Laboratories LtdAbbott Laboratories Ltd Summary of product characteristics for Norvir 100 mg tablets. Electronic Medicines Compendium Web site.http://www.medicines.org.uk/EMC/medicine/22952/SPC/Norvir+100mg+film-coated+tablets/. Accessed December 11, 2011.
 
University of Liverpool Drug Interactions Web site.http://www.hiv-druginteractions.org/Interactions.aspx. Accessed December 11, 2011.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543